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A commentary on 
Sublingual allergen immunotherapy in HIV-positive patients 
by Iemoli E, Borgonovo L, Fusi A, Magni C, Ricci ED, Rizzardini G, et al. Allergy (2016) 71(3):412–5. 
doi: 10.1111/all.12713
I read with great interest the Brief Communication by Iemoli et al., on the latest issue of Allergy, 
where the authors reported that HIV-patients, undergoing anti-retroviral therapy (HAART) and 
sublingual immunotherapy (SLIT) to grass-pollen allergy, reported clinical benefits. The authors 
evaluated the outcome by the analysis of total combined score (TCS) and a quality of life (QoL) 
questionnaire (1) and concluded that SLIT was not only clinically effective but also safe and did 
not change any immune-virological parameter in HIV-infected individuals. Patients underwent 
immunotherapy while being in active HAART for at least 5 years and suffering from airway allergy 
even since many years before HIV infection. The authors limited their blood testing on CD4/CD8 
ratio, CD4 amount, and HIV viral load. Previous reports have shown similar positive outcome, in 
SLIT or subcutaneous immunotherapy (2, 3).
The immunological status of a subject suffering from AIDS, though under retroviral therapy, 
deserves particular attention to her/his immune system, particularly about the role of the different 
CD4+ T-cell subpopulations. Actually, HIV-infected patients, undergoing HAART, are particularly 
susceptible to atopic predispositions and chronic allergy and, moreover, subjects immunization may 
enhance T-cell responses (3). Iemoli et  al. reported that almost the whole cohort of individuals 
suffered from allergic rhinitis and 70% from asthma [(1), see Table 1].
The presence of allergic inflammation prior infection and the immune response of HIV-infected 
patients being under HAART may have a major role to diagnose and treat these individuals for pollen 
allergy (4). In this context, as Th-17 are strategic in allergy and may also contribute to the patho-
genesis of classically recognized Th2-mediated allergic disorders, such as asthma, authors should be 
suggested to further investigate the role of Th-17 in these patients undergoing SLIT. During HIV 
infection, the role of Th17 may be impaired (5). In particular, Th-17 cells may be reduced in the gut 
of HIV-infected individuals, an occurrence that could lead to bacterial translocation from the gut 
lumen to the systemic circulation and chronic activation of the immune response (6). The paper by 
Iemoli et al. did not take into account the possible role exerted by these cells in mucosal immunity 
during oral immunotherapy in HIV-infected patients. From a pneumological point of view, the 
CD4+Th17 response, even in subjects with mild asthma due to pollen allergy, may activate CD177+ 
neutrophils, which can produce IL-17, accumulate in the lung, and exacerbate chronic allergy (7). 
This should occur in non-immune compromised patients. As during HIV infection, mucosal Th-17 
function is altered and HAART is unable to restore the normalization of mucosal Th17 activity 
(8), the dysregulation of Th17 function might have a positive-driven role toward the resulted out-
come from SLIT. Chronic inflammation during asthma is characterized by the fundamental role 
2Chirumbolo HIV and Sublingual Allergen Immunotherapy
Frontiers in Immunology | www.frontiersin.org March 2016 | Volume 7 | Article 132
exerted by Th-17 and IL-23, which preferentially contributes in 
expanding Th-17, with neutrophil accumulation in airways and 
Th-2 cell-mediated basophil and eosinophil inflammation, thus 
exacerbating asthma symptoms (9). Iemoli and coworkers did not 
elucidate how much their reported outcome may depend on an 
impairment in mucosal immunity due to the Th-17/T-reg and 
Th-2 axis dysregulation.
Immune mucosal integrity is of major importance and serum 
IL-17 has even been related with allergy severity (10). The activ-
ity of Th-17 in these subjects is particularly puzzling, however. 
In HIV-infected patients, the role of CD4+Th17 is particularly 
important to elucidate the effect of immunization in these com-
promised individuals. In the article by Iemoli et al., HIV-infected 
subjects have CD4 T-cell absolute counts <500, a number com-
parable to that of the HIV discordant group reported in a recent 
paper by others, where patients reported a higher immune activa-
tion and immune exhaustion after being on HAART (11). Here, 
circulating Th17 T-cells paradoxically increased their number, 
compared with non-infected subjects (11). Effectiveness in SLIT 
in these patients may depend on the ability to restore CD4/CD8 
ratio (concordant patients), on the relationship between regula-
tory T cells and Th-17 cells and on viral load being HAART. These 
parameters should be included when allergy immunization is 
performed in HIV-infected patients, as TCS may be used simply 
as an anamnestic index. Due to possible exacerbation of chronic 
immune response in these subjects, particularly following therapy, 
further evaluation of T-cell subtypes and particularly of γδ T-cells, 
might be fundamental to optimize serum immunotherapy against 
airway allergens and its follow up and/or maintenance. Even in 
HIV-infected patients, cytokine-secreting αβ+CD4+ T-helper 2 
(Th2) cells orchestrate the type-2-driven immune response in a 
large proportion of atopic asthmatics. Th17 cells are present in 
bronchoalveolar lavage fluid of individuals with asthma. In HIV-
infected patients, the role of Th17 and T-regs or the relationship 
Th17/T-reg/Th1 should be better focused, in order to elucidate if 
during immunotherapy mucosal barrier is compromised (Th17-
depletion) or not or if allergy response is dampened (T-regs 
modulation) (12). The onset of an anergy-like state in the allergy 
response during HIV infection may be due by the initial increase 
in the T-reg/Th-17 ratio, possibly for Th-17 depletion, this may 
create some bias in the interpretation of the immunotherapy suc-
cess. Usually, HIV-infected patients are characterized by deple-
tion both in circulating Th17 and in CD161+ CD4+ T-cells, able 
to reconstitute Th17 pool, the presence of which is fundamental 
for the outcome of serum immunotherapy. This evidence raises 
some consideration if SLIT efficacy reported by the authors might 
account on a HAART-dependent recovery in mucosal Th17 activ-
ity or in an increased regulatory T cell-dependent dampening of 
allergy. The study from Iemoli et al. would gain major insights if 
blood specimens were analyzed for flow cytometry investigation 
of T-cell subtypes.
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